CATX - Perspective Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$13.33
DETAILS
HIGH:
$16.00
LOW:
$12.00
MEDIAN:
$12.00
CONSENSUS:
$13.33
UPSIDE:
234.92%
About Perspective Therapeutics, Inc. (https://www.perspectivetherapeutics.com)
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Johan Spoor | Chief Executive Officer & Director | 1972 | $1,102,000 USD |
| Markus Puhlmann | Chief Medical Officer | 1966 | $737,400 USD |
| Jonathan R. Hunt | Chief Accounting Officer | 1967 | $611,165 USD |
| Joel David Sendek | CFO & Principal Financial Officer | 1967 | $574,294 USD |
| Amos Hedt PGradDip | Chief Business Strategy Officer | – | – |
| Andrew Bright | Executive Vice President of Brachytherapy | – | – |
| Annie J. Cheng | Vice President of Investor Relations | 1976 | – |
| Chris Nenno | General Counsel & Corporate Secretary | – | – |
| Michael K. Schultz | Chief Science Officer | – | – |
| Shane Cobb | Executive Vice President of Operations | – | – |